News for Oncolytics Biotech, Inc. (USA) - Google Finance

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase ...

Wed, 22 May 2013 10:30:54 GMT

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase ...
PR Newswire (press release) - May 22, 2013

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of ...

What's Next: Zale Corporation (NYSE:ZLC), Multiband Corp (NASDAQ:MBND ...

Wed, 22 May 2013 15:18:16 GMT

What's Next: Zale Corporation (NYSE:ZLC), Multiband Corp (NASDAQ:MBND ...
Openglobe - May 22, 2013

Zale Corporation (NYSE:ZLC) shares jumped 30.93% to $7.07. The company on May 22 reported net income of $5.1 million, or 13 cents per share, compared with a loss of $4.5 million, or 14 cents per share, in the same quarter the year before.

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH - NASDAQ

BRIEF-Oncolytics Biotech US-listed shares jump 10.3 percent premarket

Wed, 22 May 2013 12:13:53 GMT

BRIEF-Oncolytics Biotech US-listed shares jump 10.3 percent premarket
Reuters - May 22, 2013

NEW YORK | Wed May 22, 2013 8:08am EDT. NEW YORK May 22 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares jump 10.3 percent to $3 in premarket after phase 2 metastatic melanoma trial results. Stocks · Markets · Healthcare ...

Oncolytics Biotech® Inc. to Present at 2013 Jefferies Global Healthcare ...

Tue, 04 Jun 2013 10:31:31 GMT

Oncolytics Biotech® Inc. to Present at 2013 Jefferies Global Healthcare ...
PR Newswire (press release) - Jun 4, 2013

... Repost.us. CALGARY, June 4, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 2013 Jefferies Global Healthcare Conference on ...

Oncolytics Biotech Inc. (USA) (NASDAQ:ONCY) falls from high, US Geothermal ...

Wed, 22 May 2013 18:24:37 GMT

Oncolytics Biotech Inc. (USA) (NASDAQ:ONCY) falls from high, US Geothermal ...
GSPInsider - May 22, 2013

Miami, FL 05/22/2013 (GDPInsider) - Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) opened the day at $2.97 and hit a high of $3.06 and a low of $2.83 and is currently down by 1.10% to trade at $2.69, with a volume of about 1.60 million.

Oncolytics cancer drug meets mid-stage trial goal, shares rise - Reuters
Oncolytics rises on melanoma study results - MSN Money

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) down by 3.68%, Mitsubishi UFJ ...

Tue, 28 May 2013 06:36:31 GMT

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) down by 3.68%, Mitsubishi UFJ ...
NIS - May 28, 2013

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) closed on Friday at $2.62 per share, declining by 3.68% (-$0.10) from Thursday's closing price of $2.72.

Bio-Tech Stands Against Tech And Solar Stocks: Oncolytics Biotech, NetApp ...

Thu, 23 May 2013 12:40:39 GMT

Bio-Tech Stands Against Tech And Solar Stocks: Oncolytics Biotech, NetApp ...
Galaxy Stocks - May 23, 2013

Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) opened at $2.97 with 84.76 million outstanding shares and touched its highest price of $2.75 during the day and then finished at $2.75 by scoring +1.10%.

TOP GAINERS Pre Market Today – Saks Inc, Oncolytics Biotech, Direxion Daily ...

Wed, 22 May 2013 14:13:03 GMT

TOP GAINERS Pre Market Today – Saks Inc, Oncolytics Biotech, Direxion Daily ...
FxPips.com (blog) - May 22, 2013

The company's relative strength index is currently at 79.45 which shows that the stock is overbought. SKS's price to index ratio is 35.97, with a market cap of $2.06 billion.

Top Gainers in Pre-market Today, May 22 - MarketsNTrade

Research and Markets: Soft Tissue Sarcoma - Pipeline Review Market Report ...

Wed, 19 Jun 2013 02:34:00 GMT

Research and Markets: Soft Tissue Sarcoma - Pipeline Review Market Report ...
Wall Street Journal - 17 hours ago

... Inc. -- Infinity Pharmaceuticals, Inc. -- Prolexys Pharmaceuticals, Inc. -- ZIOPHARM Oncology, Inc. -- Novartis AG -- Auxilium Pharmaceuticals, Inc. -- Pfizer Inc. -- Cell Therapeutics, Inc. -- Menarini Group -- EntreMed, Inc. -- Oncolytics Biotech ...

Unexpected Volume Gainers: Signet, Multiband, Dycom, Oncolytics

Thu, 23 May 2013 13:21:23 GMT

Unexpected Volume Gainers: Signet, Multiband, Dycom, Oncolytics
Galaxy Stocks - May 23, 2013

Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) traded at $2.75 by increasing +1.10% with price volatility of 6.80% for a week and 4.85% for a month.